
Product name:	SENP6 Rabbit Polyclonal Antibody
Cat number:	ABN17729
Conjugate:	Unconjugated
Size:	100µL
Clone:	Polyclonal
Concentration:	1mg/ml
Host:	Rabbit
Isotype:	IgG
Immunogen:	The antiserum was produced against synthesized peptide derived from human SENP6. AA range:1042-1091
Reactivity:	Human,Rat,Mouse
Applications:	IHC 1:100-1:300,ICC/IF 1:50-1:200,ELISA 1:5000-1:20000
Purification:	Affinity purification
Form:	Liquid
Buffer:	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.
Storage:	Store at 4°C short term. Aliquot and store at -20°C for 12 months. Avoid freeze/thaw cycles.
Background:	Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]). SENPs also display isopeptidase activity for function:Protease that deconjugates SUMO1, SUMO2 and SUMO3 from targeted proteins. Does not seem to be involved in the processing of full-length SUMO proteins to their mature forms. Deconjugates SUMO1 from RXRA, leading to transcriptional activation. May act preferentially on substrates containing 3 or more SUMO2 or SUMO3 moieties.,similarity:Belongs to the peptidase C48 family.,subunit:Interacts with RXRA.,tissue specificity:Highly expressed in reproductive organs, such as testis, ovary and prostate.,